TipRanks
Advertisement
Advertisement

HK:0013 Stock Latest News

HUTCHMED Backs AstraZeneca’s U.S. Filing for ORPATHYS–TAGRISSO Lung Cancer Combo
Company AnnouncementsHUTCHMED Backs AstraZeneca’s U.S. Filing for ORPATHYS–TAGRISSO Lung Cancer Combo
14d ago
Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC
PremiumThe Fly
Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC
14d ago
AZN
HCM
Hutchmed initiates Phase Ia part of trial of HMPL-A830
PremiumThe Fly
Hutchmed initiates Phase Ia part of trial of HMPL-A830
15d ago
HCM
HUTCHMED launches first-in-human global trial of novel KRAS-EGFR cancer therapy HMPL-A830
PremiumCompany Announcements
HUTCHMED launches first-in-human global trial of novel KRAS-EGFR cancer therapy HMPL-A830
15d ago
HUTCHMED to showcase pivotal lung cancer and broad oncology data at ESMO 2026
PremiumCompany Announcements
HUTCHMED to showcase pivotal lung cancer and broad oncology data at ESMO 2026
19d ago
Hutchmed price target raised to $18 from $16 at BofA
PremiumThe FlyHutchmed price target raised to $18 from $16 at BofA
22d ago
HCM
Hutchmed upgraded to Buy from Hold at HSBC
Premium
The Fly
Hutchmed upgraded to Buy from Hold at HSBC
1M ago
HCM
Hutchmed extends rally to 17% after Daiwa upgrades to Buy
Premium
The Fly
Hutchmed extends rally to 17% after Daiwa upgrades to Buy
1M ago
HCM
Hutchmed upgraded to Buy from Hold at Daiwa
PremiumThe Fly
Hutchmed upgraded to Buy from Hold at Daiwa
1M ago
HCM
Hutchmed rises 13.7%
PremiumThe Fly
Hutchmed rises 13.7%
1M ago
HCM
Hutchmed, GSK enter HMPL-A830 commercialization agreement
PremiumThe Fly
Hutchmed, GSK enter HMPL-A830 commercialization agreement
1M ago
GSK
HCM
HUTCHMED Licenses First-in-Class KRAS-EGFR Cancer Therapy to GSK in US$1.3 Billion Deal
PremiumCompany Announcements
HUTCHMED Licenses First-in-Class KRAS-EGFR Cancer Therapy to GSK in US$1.3 Billion Deal
1M ago
HUTCHMED’s ORPATHYS–TAGRISSO Combo Delivers First-Line PFS Gain in MET-Driven Lung Cancer
PremiumCompany AnnouncementsHUTCHMED’s ORPATHYS–TAGRISSO Combo Delivers First-Line PFS Gain in MET-Driven Lung Cancer
1M ago
HUTCHMED’s ORPATHYS Combo Delivers First-Line Benefit in MET-Driven Lung Cancer
Premium
Company Announcements
HUTCHMED’s ORPATHYS Combo Delivers First-Line Benefit in MET-Driven Lung Cancer
1M ago
HUTCHMED Wins China NMPA Nod for ATLED in Advanced Liver Cancer
Premium
Company Announcements
HUTCHMED Wins China NMPA Nod for ATLED in Advanced Liver Cancer
2M ago
HUTCHMED Flags Director’s Link to Insolvent Israeli Medtech Firm, Sees No Impact
PremiumCompany Announcements
HUTCHMED Flags Director’s Link to Insolvent Israeli Medtech Firm, Sees No Impact
2M ago
Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso
PremiumThe Fly
Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso
2M ago
HCM
HUTCHMED’s ORPATHYS–TAGRISSO combo delivers Phase III survival gains in MET-driven lung cancer
PremiumCompany Announcements
HUTCHMED’s ORPATHYS–TAGRISSO combo delivers Phase III survival gains in MET-driven lung cancer
2M ago
HUTCHMED’s China Rebound and Global FRUZAQLA Push Power 2026 Interim Results
PremiumCompany Announcements
HUTCHMED’s China Rebound and Global FRUZAQLA Push Power 2026 Interim Results
3M ago
Hutchmed price target lowered to $14 from $16 at Goldman Sachs
PremiumThe FlyHutchmed price target lowered to $14 from $16 at Goldman Sachs
3M ago
HCM
Hutchmed price target lowered to $17 from $20 at BofA
Premium
The Fly
Hutchmed price target lowered to $17 from $20 at BofA
3M ago
HCM
Hutchmed announces China NMPA approval for Orpathys NDA
Premium
The Fly
Hutchmed announces China NMPA approval for Orpathys NDA
3M ago
HCM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >